Coherence of the knowledge base and the firm's innovative performance: Evidence from the U.S. pharmaceutical industry

Journal of Industrial Economics

Volumn 53, Issue 1, 2005, Pages 123-142

  Nesta, Lionel ^a   Saviotti, Pier Paolo ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 16644363195     PISSN: 00221821     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-1821.2005.00248.x     Document Type: Article

References (45)

1. Archibugi, D., 1992, 'Patenting as an Indicator of Technological Innovation: A Review,' Science and Public Policy, 19(6), pp. 357-368.
2. Arora, A. and Gambardella, A., 1990, 'Complementarities and External Linkages: The Strategies of The Large Firms in Biotechnology,' Journal of Industrial Economics, 38(4), pp. 361-379.
3. Arora, A. and Gambardella, A., 1994a, 'Evaluating Technological Information and Utilizing It: Scientific Knowledge, Technological Capability, and External Linkages in Biotechnology,' Journal of Economic Behavior and Organization, 24(1), pp. 91-114.
4. Arora, A. and Gambardella, A., 1994b, 'The Changing Technology of Technological Change: General and Abstract Knowledge and the Division of Innovative Labour,' Research Policy, 23(5), pp. 523-532.
5. Boisot, M. H., 1995, 'Is Your Firm a Creative Destroyer? Competitive Learning and Knowledge Flows in the Technological Strategies of Firms,' Research Policy, 24(4), pp. 489-506.
6. Breschi, S.; Lissoni, F. and Malerba, F., 2003, 'Knowledge-relatedness in Firm Technological Diversification,' Research Policy, 32(1), pp. 69-87.
7. Cameron, A. C. and Trivedi, P. K., 1986, 'Econometric Models Based on Count Data: Comparisons and Applications of Some Estimators and Tests,' Journal of Applied Econometrics, 1(1), pp. 29-53.
8. Carpenter, M. P.; Narin, F. and Woolf, P., 1981, 'Citation Rates to Technologically Important Patents,' World Patent Information, 3(4), pp. 160-163.
9. Cockburn, I. M. and Henderson, R. M., 1998, 'Absorptive Capacity, Co-authoring Behaviour and the Organization of Research in Drug Discovery,' Journal of Industrial Economics, 46(2), pp. 157-182.
10. Comanor, W. S., 1965, 'Research and Technical Change in the Pharmaceutical Industry,' Review of Economics and Statistics, 47(2), pp. 1178-1217.
11. Gambardella, A., 1995, Science and Innovation: The U.S. Pharmaceutical Industry during the 1980s, (Cambridge University Press).
12. Grabowski, H. G. and Vernon, J. M., 1994, 'Innovation and Structural Change in Pharmaceuticals and Biotechnology,' Industrial and Corporate Change, 3(2), pp. 435-449.
13. Graves, S. B. and Langowitz, N. S., 1993, 'Innovative Productivity and Returns to Scale in the Pharmaceutical Industry,' Strategic Management Journal, 14(8), pp. 593-605.
14. Griliches, Z., 1979, 'Issues in Assessing the Contribution of Research and Development to Productivity Growth,' Bell Journal of Economics, 10(1), pp. 92-116.
15. Hall, B. H.; Jaffe, A. B. and Trajtenberg, M., 2000, 'Market Value and Patent Citations: A First Look,' NBER Working Paper No. 7,741.
16. Hall, B. H.; Jaffe, A. B. and Trajtenberg, M., 2001, 'The NBER Patent Citation Data File: Lessons, Insights and Methodological Tools,' NBER Working Paper 8,498.
17. Henderson, R. M. and Cockburn, I., 1994, 'Measuring Competence? Exploring Firm Effects in Pharmaceutical Research,' Strategic Management Journal, 15, Special Issue Winter, pp. 63-84.
18. Henderson, R. M. and Cockburn, I., 1996, 'Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery,' Rand Journal of Economics, 27(1), pp. 32-59.
19. Jacobs, S. H., 1998, 'Due Diligence: Valuations of Biotechnology Patents in the 21st Century,' Genetic Engineering Guide to Biotechnology Companies, (Mary Ann Liebert, Inc.), pp. xi-xii.
20. Jaffe, A. D., 1986, 'Technological Opportunity and Spillovers of R&D:Evidence From Firms' Patents, Profits and Market Values,' American Economic Review, 76(5), pp. 984-1001.
21. Jaffe, A.D.; Trajtenberg, M. and Fogarty, M. S., 2000, 'Knowledge Spillovers and Patent Citations: Evidence from A Survey of Inventors,' American Economic Review, Papers and Proceedings, pp. 215-218.
22. Jensen, E. J., 1987, 'Research Expenditures and the Discovery of New Drugs,' Journal of Industrial Economics, 36(1), pp. 83-95.
23. Kenney, M., 1986, Biotechnology: The University-Industry Complex, (Yale University Press).
24. Lambert, D., 1992, 'Zero-Inflated Poisson Regression, with an Application to Defects in Manufacturing,' Technometrics, 34, pp. 1-14.
25. Leonard-Barton, D., 1992, 'Core Capabilities and Core Rigidities: A Paradox in Managing New Product Development,' Strategic Management Journal, 13, pp. 111-125.
26. McCullagh, P. and Neider, J. A., 1989, Generalized Linear Models, (Chapman and Hall).
27. McKelvey, M. D., 1996, Evolutionary Innovations: The Business of Biotechnology, (Oxford University Press).
28. Montgomery, C. A., 1982, 'Diversification, Market Structure and Firm Performance: An Extension of Rumelt's Work,' Academy of Management Journal, 25, pp. 299-307.
29. Montgomery, C. A. and Hariharan, S., 1991, 'Diversified Expansion by Large Established Firms,' Journal of Economic Behavior and Organization, 15(1), pp. 71-89.
30. Orsenigo, L., 1989, The Emergence of Biotechnology, (St. Martin's Press).
31. Palepu, K., 1985, 'Diversification Strategy, Profit Performance and the Entropy Measure,' Strategic Management Journal, 6, pp. 239-255.
32. Pavitt, K., 1988, 'Uses and Abuses of Patent Statistics,' in A. van Raan, ed., Handbook of Quantitative Studies of Science and Technologies, (Elsevier Science Publishers).
33. Penrose, E., 1959, The Theory of the Growth of the Firm, (Basil Blackwell).
34. Price de Solla, D. J., 1963, Little Science, Big Science, (Columbia University Press, New York and London).
35. Pyka, A. and Saviotti, P. P., 2002, 'Innovation Networks in the Biotechnology Based Sectors,' in Pyka, A. and Kuppers, G. eds., Innovation Networks: Theory and Practice, (Cheltenham: Edward Elgar).
36. Ramanujam, V. and Varadarajan, P., 1989, 'Research on Corporate Diversification: A Synthesis,' Strategic Management Journal, 10, pp. 523-551.
37. Rumelt, R. P., 1974, Strategy, Structure, and Economic Performance, (Harvard Business School Press).
38. Saviotti, P. P., 1998, 'Industrial Structure and the Dynamics of Knowledge Generation in Biotechnology,' in Senker, J. ed., Biotechnology and the Competitive Advantage, (Cheltenham, Edward Elgar). pp. 19-43.
39. Schwartzman, D., 1976, Innovation in the Pharmaceutical Industry, (The Johns Hopkins University Press).
40. Scott, J. T. and Pascoe, G., 1987, 'Purposive Diversification of R&D in Manufacturing,' Journal of Industrial Economics, 36(2), pp. 193-205.
41. Scott, J. T., 1993, Purposive Diversification and Economic Performance (Cambridge; New York and Melbourne: Cambridge University Press.
42. Teece, D. J. and Pisano, G., 1994, 'The Dynamic Capabilities of Firms: An Introduction,' Industrial and Corporate Change, 3(3), pp. 537-556.
43. Teece, D. J; Rumelt, R.; Dosi, G. and Winter, S., 1994, 'Understanding Corporate Coherence: Theory and Evidence,' Journal of Economic Behavior and Organisation, 23(1), pp. 1-30.
44. Trajtenberg, M., 1990, 'A Penny for Your Quotes: Patent Citations and the Value of Innovations,' The Rand Journal of Economics, 21(1), pp. 172-187.
45. Vernon, J. M. and Gusen, P., 1974, Technical Change and Firm Size: The Pharmaceutical Industry,' Review of Economics and Statistics, 56(3), pp. 294-302.